Acalabrutinib
-
Acalabrutinib
structure -
-
CAS No:
1420477-60-6
-
Formula:
C26H23N7O2
-
Chemical Name:
Acalabrutinib
-
Synonyms:
ACP196;ACP-196;acalabrutinib;Benzamide, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-;ACP196,Acalabrutinib;4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide;EOS-60753;(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
- Categories:
-
CAS No:
Description
Acalabrutinib (ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 3 nM, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. ACP-196 has improved target specificity over ibrutinib with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.
ChEBI: Acalabrutinib is a member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a secondary carboxamide, a member of benzamides, a member of pyridines, an aromatic amine, a pyrrolidinecarboxamide, an imidazopyrazine, a ynone and a tertiary carboxamide.
Class: non-receptor tyrosine kinaseTreatment: CLL, SLL, MCLOral bioavailability = 25%Elimination half-life = 0.9 hProtein binding = 97.5%
Acalabrutinib Use and Manufacturing
Acalabrutinib, is an experimental anti-cancer drug and a selective Bruton's tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL).
Recommended Suppliers of Acalabrutinib
-
![China]()
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives -
![China]()
CN
5 YRS
Business licensed Certified factoryManufactory Supplier of Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst,Chemical Materials,Chem&Pharm Intermediates,Organic Intermediates,Feed AdditiveInquiryCAS No.: 1420477-60-6Grade: Industrial GradeContent: 99% -
![China]()
CN
5 YRS
Business licensedTrader Supplier of PVC resin,pvc paste resin,melamineInquiryCAS No.: 1420477-60-6Grade: Industrial GradeContent: 99% -
![China]()
CN
1 YR
Business licensedTrader Supplier of Pharmaceutical intermediate/API， and fragrances APIInquiryCAS No.: 1420477-60-6Grade: Pharmaceutical GradeContent: 99% -
![China]()
CN
1 YR
Business licensedTrader Supplier of Peptides,API,Intermediate
Learn More Other Chemicals
-
3-(3-CHLOROPROPYLCARBAMOYL)BENZENEBORONIC ACID
874288-10-5
-
3-Pyridinecarboxylic acid, 2,6-dichloro-, ethyl ester
58584-86-4
-
(+)-Mesembrenone
468-54-2
-
1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, hydrochloride (1:1) Formula
230615-52-8
-
(4-acetyloxyphenyl)-(4-acetyloxyphenyl)imino-oxidoazanium Formula
79030-44-7
-
1-(4-Methoxy-phenyl)-2,5-dimethyl-1H-pyrrole-3-carbaldehyde Formula
347331-30-0
-
2,2'-DIAMINODIPHENYL SULFIDE Structure
5873-51-8
-
AC-ARG-PHE-MET-TRP-MET-ARG-NH2 Structure
152274-65-2
-
What is 1,1-Dimethylethyl 2-bromo-2-methylpropanoate
23877-12-5
-
What is 1,3-Dichloro-2,4-difluorobenzene
36556-37-3